Treatment of glial tumors with glutamate antagonists

Abstract

The present invention relates to a method of treating glial tumors in a subject, which includes providing a glutamate antagonist or a NMDA receptor antagonist and administering the glutamate antagonist or NMDA receptor antagonist to a subject with a glial tumor of the brain or spinal cord under conditions effective to treat the glial tumor.

1 . A method of treating glioblastoma in a subject comprising: 
 providing a NMDA receptor antagonist and    administering the NMDA receptor antagonist to a subject with a glioblastoma under conditions effective to treat the glioblastoma and prevent spread of tumor cells, wherein the NMDA receptor antagonist is administered at a dose lower than that at which glutamate antagonists cause direct cytotoxicity.    
   
   
       2 . The method according to  claim 1 , wherein said glioblastoma is located in the brain of the subject.  
   
   
       3 . The method according to  claim 1 , wherein said glioblastoma is located in the spinal cord of the subject.  
   
   
       4 . The method according to  claim 1 , wherein said glioblastoma is malignant.  
   
   
       5 . The method according to  claim 1 , wherein said glioblastoma is benign.  
   
   
       6 . The method according to  claim 1 , wherein said NMDA receptor antagonist blocks glutamate finction at NMDA receptor complexes.  
   
   
       7 . The method according to  claim 6 , wherein said NMDA receptor antagonist binds to a NMDA receptor.  
   
   
       8 . The method according to  claim 6 , wherein said NMDA receptor antagonist interacts with NMDA ion channels.  
   
   
       9 . The method according to  claim 6 , wherein said NMDA receptor antagonist is an antibody to NMDA receptors.  
   
   
       10 . The method according to  claim 1 , wherein the subject is a mammal.  
   
   
       11 . The method according to  claim 10 , wherein the mammal is a human subject.  
   
   
       12 . The method according to  claim 10 , wherein said administering is carried out orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, by intranasal instillation, by implantation, by intracavitary or intravesical instillation, intraocularly, intraarterially, intralesionally, transdernally, or by application to mucous membranes.  
   
   
       13 . The method according to  claim 1 , wherein said NMDA receptor antagonist is present in a pharmaceutical composition comprising the NMDA receptor antagonist and a pharmaceutically-acceptable carrier.